EIKN
Q4 2026 EPS Estimate
$-1.75
Nov 12, 2026

Analyst Sentiment

Wall St. Consensus
Sell
1 analyst·Low coverage
25
Score
0 Buy (0%)0 Hold (0%)1 Sell (100%)
Rating Breakdown
Strong Buy
00%
Buy
00%
Hold
00%
Sell
1100%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$5.00
-58.4%
Consensus
$5.00
-58.4%
Bull
$5.00
-58.4%
12-Month Target Range1 analyst
$5.00$5.00$5.00
Current $12.01Consensus
Current Price
$12.01
Above Consensus
$7.01

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev
EPS
FY2028
Rev
EPS
FY2029
Rev
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$50M$134M
Low$50M$134M
High$50M$134M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-379M$-338M$-304M$-284M$-232M
Low$-404M$-418M$-380M$-284M$-232M
High$-359M$-258M$-228M$-284M$-232M
EPS Avg$-6.91$-6.66$-5.82$-5.25$-4.29
Low$-7.46$-7.71$-7.01$-5.25$-4.29
High$-6.64$-4.77$-4.21$-5.25$-4.29
Analysts (Rev / EPS) / 5 / 5 / 31 / 11 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-91M$-93M$-96M$-98M$-98M$-90M
Low$-97M$-105M$-96M$-98M$-98M$-90M
High$-83M$-79M$-96M$-98M$-98M$-90M
EPS Avg$-1.69$-1.72$-1.78$-1.82$-1.82$-1.66
Low$-1.79$-1.94$-1.78$-1.82$-1.82$-1.66
High$-1.53$-1.46$-1.78$-1.82$-1.82$-1.66
Analysts (Rev / EPS) / 3 / 3 / 1 / 1 / 1 / 1

Earnings Surprises

Recent Analyst Actions

May 12, 2026Wedbush
Eikon Therapeutics price target lowered to $5 from $7 at Wedbush
Target:$5.00
-54.4%from $10.97
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.